While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.

Intensive chemotherapy combined with second- or third-generation tyrosine kinase inhibitors improves survival in patients ...

A group of researchers at VCU Massey Comprehensive Cancer Center was awarded $13 million by the National Cancer Institute.

Nurix Therapeutics Inc. (NRIX) presented positive clinical data from its ongoing Phase 1a/1b clinical trial of NX-5948, an orally ...

The study found that the price tag for the second-generation Bruton tyrosine kinase inhibitor would need to be reduced by 30% ...

The Tyrosine Protein Kinase JAK1 pipeline drugs market research report outlays comprehensive information on the Tyrosine Protein Kinase JAK1 targeted therapeutics, complete with analysis by ...

Investigators say adding RNA interference (RNAi) therapy to current treatment modalities may improve outcomes in patients ...

Exelixis is advancing its pipeline with zanalintinib and XB010, exploring new avenues in oncology beyond its cabozantinib ...

Researchers at the Weizmann Institute have created a composite plastic that degrades easily using bacteria and is cheap and ...

Tyrosine, a non-essential amino acid, is vital for the production of neurotransmitters like dopamine, norepinephrine, and epinephrine. These neurotransmitters play an essential part in regulating ...

Cyrus M. Khan, MD, highlights some of the most recent and significant advancements in chronic lymphocytic leukemia treatment.